Toxicities Associated with Docetaxel-Based Regimens in the Adjuvant Treatment of Early-Stage Breast Cancer: A Multicenter Prospective Real-Life Experience

Abstract

Background: The present study reports on the efficacy and safety of adjuvant docetaxel in real-life patients with early-stage breast cancer. Methods: This is a prospective, multicenter, post-marketing study that evaluates the efficacy and safety of docetaxel-based regimens in patients with early breast cancer treated between 2007 and 2012. Results: A total of 698 female breast cancer patients receiving adjuvant docetaxel-based regimens were included in this study. Docetaxel monotherapy was administered in 4.2%, whilst most patients received polychemotherapy. Non-hematological adverse events included skin reactions in 32.7% of the subjects. Multiple adverse events were reported and most commonly included asthenia (66.5%), alopecia (43.4%), and diarrhea (24.2%). It is noteworthy that no fatal toxicities occurred. Several hematological adverse events were reported during treatment, with anemia being the most common. Conclusion: The results of this real-life experience, characterized by a relatively large sample size and long follow-up, confirm that docetaxel is effective and well tolerated in early-stage breast cancer patients.

Natural therapeutics for cancer treatment: success, challenges, and prospect

“…Although the compound has high potency toward killing several tumor types, like paclitaxel, it also has been associated with toxicity towards normal cells and tissue. [26] Vinca alkaloids Vinca alkaloids (VAs) are a diverse set of phytochemicals derived from Catharanthus roseus (Apocynaceae), a group of microtubule-targeted anticancer agents are used in the clinic for the treatment of several types of cancers, including breast, liver, leukemia, testicular cancer, and lung cancer. Vindesine, vincristine, and vinblastine are the most often used VAs (Fig.…”

“…Although the compound has high potency toward killing several tumor types, like paclitaxel, it also has been associated with toxicity towards normal cells and tissue. [26]…”

Kajian Efek Samping Obat Kemoterapi Dosetaksel Pada Kanker Payudara Di RS Bhayangkara Kediri

“…Beberapa efek samping yang dilaporkan dan paling sering adalah asthenia (66,5%), alopecia (43,4%), dan diare (24,2%). Sedangkan pada efek samping hematologi, kejadian anemia merupakan efek samping terbanyak dengan persentase 15,9% 6 . Penelitian mengenai efek samping obat kemoterapi di Indonesia masih terbatas.…”

“…Adanya efek samping perubahan warna kuku ini juga dilaporkan oleh Rassy dkk (2018). Pada penelitian tersebut sebanyak 16,9% dari 698 subyek mengalami perubahan kuku dengan berbagai tingkat keparahan 6 . Perubahan kuku terjadi setelah beberapa siklus kemoterapi dosetaksel yang cenderung sembuh secara bertahap selama beberapa minggu meskipun pengobatan dilanjutkan.…”